Magazine Article | December 1, 2021

What's The Biopharma Financial View For 2022?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

If we thought investment in the biopharmaceutical industry was hot last year, then 2021 proved downright volcanic. Not only did we see plenty of “traditional” IPOs, but the special purpose acquisition corporation (SPAC) route that came into favor in 2020 also seemed to gain momentum. But the world of biopharmaceutical finance is more than what happens in the markets. For example, initiatives to halt climate change have executives reconsidering how their companies conduct business in striving for a net-zero carbon footprint. Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: